Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;48(10):1463-1473.
doi: 10.1111/1346-8138.16022. Epub 2021 Jul 1.

Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database

Akimichi Morita  1 , Nirali Kotowsky  2 , Ran Gao  2 , Reiko Shimizu  3 , Yukari Okubo  4
Affiliations

Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: Results from the Medical Data Vision claims database

Akimichi Morita et al. J Dermatol. 2021 Oct.

Abstract

Generalized pustular psoriasis (GPP) is a rare and severe systemic, neutrophilic skin disease. To date, accurate clinical profiling of patients with GPP remains poorly understood. In this study, we present the characteristics and estimate the burden of disease in patients with GPP compared with those with plaque psoriasis, in Japan. This retrospective study was conducted using the Medical Data Vision database between January 1, 2015, and December 31, 2019. Patients with at least one confirmed inpatient or outpatient diagnostic code for GPP (L40.1) or psoriasis vulgaris (L40.0) were included for analysis. The main outcome measures included comparisons of the prevalence of comorbidities, medication use, and healthcare resource utilization between patients with GPP, patients with plaque psoriasis, and a general population-matched cohort. In total, 718 patients with GPP and 27,773 patients with plaque psoriasis were identified. Patients with GPP were more likely to be female than those with plaque psoriasis (51.6% vs. 38.7%). During the 12-month follow-up period, patients with GPP were more likely to experience comorbidities than those with plaque psoriasis, including psoriatic arthritis, other forms of psoriasis, osteoporosis, interstitial pneumonia, and peptic ulcer disease. Medication use also differed between those with GPP and those with plaque psoriasis: patients with GPP were more likely to be prescribed antibiotics and psychiatric medication. Patients with GPP were also more likely to require more healthcare resource utilization with longer hospitalizations than those with plaque psoriasis. Overall, in Japan, patients with GPP have a higher burden of illness than those with plaque psoriasis.

Keywords: generalized pustular psoriasis; psoriasis; pustular psoriasis; rare; real-world evidence.

PubMed Disclaimer

Conflict of interest statement

R Gao, N Kotowsky, and R Shimizu are employees of Boehringer Ingelheim. A Morita declares receiving research grants, consulting fees, and/or speaker's fees from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi‐Iko, Nippon Kayaku, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio. Y Okubo declares receiving research grants from Eisai, Torii, Maruho, and Shiseido, and has current consulting/advisory board agreements and/or speakers bureau and/or clinical trials from AbbVie, Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen Pharma, JIMRO, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho, Tanabe‐Mitsubishi, Torii, and UCB Pharma.

Figures

FIGURE 1
FIGURE 1
Study design. †Patients were eligible to enter a cohort when they fulfilled all study criteria at index date (a confirmed diagnosis and ≥1 DPC encounter during the 6 months before the index date). DPC, diagnostic procedure combination; GPP, generalized pustular psoriasis
FIGURE 2
FIGURE 2
Study population. DPC, diagnostic procedure combination; GPP, generalized pustular psoriasis; PPP, palmoplantar pustulosis
FIGURE 3
FIGURE 3
Most common comorbidities in patients with GPP during the 12‐month follow‐up period. COPD, chronic obstructive pulmonary disease; GPP, generalized pustular psoriasis
FIGURE 4
FIGURE 4
Dermatologic medication use during the 12‐month follow‐up period on or after the qualifying claim date. GPP, generalized pustular psoriasis; TNF, tumor necrosis factor
FIGURE 5
FIGURE 5
Most common concomitant medication burden during the 12‐month follow‐up period. COPD, chronic obstructive pulmonary disease; GPP, generalized pustular psoriasis
See this image and copyright information in PMC

References

    1. Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–9. - PubMed
    1. Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235–70. - PubMed
    1. Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:87–93. - PMC - PubMed
    1. Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF, et al. Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53:676–84. - PubMed
    1. Johnston A, Xing X, Wolterink L, Barnes DH, Yin ZQ, Reingold L, et al. IL‐1 and IL‐36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20. - PMC - PubMed

Grants and funding